

(26) AJ Jouhar and MF Grayson (1973)

International Aspects of Drug Evaluation and Usage: based on an international meeting of medical advisers to the pharmaceutical industry organized by the Association of Medical Advisers to the Pharmaceutical Industry, London, April 1972

Edinburgh: Churchill Livingstone

Preamble

For details of the second and subsequent International Meetings of Medical Advisers in the Pharmaceutical Industry see no. (35) below.

Aims

This book records the proceedings of the International Meeting of Medical Advisers in the Pharmaceutical Industry, which took place in London between April 17th and 20th, 1972. The meeting was conceived as an attempt to assess the current state of the evaluation and use of drugs throughout the world, as seen through the eyes of medically qualified people working in the pharmaceutical industry. This concept was embodied in a message given by the meeting's patron, His Royal Highness the Duke of Edinburgh KG, who wrote: "The need to establish the principles for evaluation of therapeutic agents is becoming progressively more important as the stream of new products pouring from the laboratories increases every year. Medical advisers, placed as they are between manufacturer and consumer, have a very delicately balanced responsibility. While they are employed as advisers to the industry the practising medical profession and the public at large are equally dependent on them for advice and protection." The meeting brought together physicians, scientists and others from the pharmaceutical industry, research institutes and medical practice from more than thirty nations (Preface, page vii).

Contents (xvi + 374 pages)

Foreword (EF Scowen)

Preface (AJ Jouhar, MF Grayson)

Chairmen

List of Contributors

Section I: Extrapolation of laboratory and animal investigations to investigations in man

1. The choice of the animal model (RE Lister)
2. Pharmacological screening procedures (WR Buckett)
3. The confirmation in man of the metabolic data found for drugs in animals (DE Hathway)
4. Toxicological testing – predictive value for clinical experience (R Hill)
5. Teratogenicity (FM Sullivan)
6. Preclinical evaluation of new drugs (B Berde)

Section II: Human and clinical pharmacology

7. The role of a department of clinical pharmacology in the pharmaceutical industry (FB Nicolls)
8. The role of academic clinical pharmacology in relation to industry (DR Laurence)
9. Relationships between industry and clinical pharmacology departments: some personal reflections (AD Munro-Faure)
10. Methods in clinical pharmacology: introduction (JR Mitchell, BB Brodie)
11. Pharmacology of contraceptive steroids (GIM Swyer)
12. The evaluation of beta adrenergic blocking drugs in man (JD Fitzgerald)

13. Methodology in clinical pharmacology: assessment of diuretics (AF Lant)
- Section III: Clinical evaluation of drugs
14. Clinical evaluation: what, why and how? (C Maxwell)
 15. Methodologies in drug assessment using computer techniques (PJ Fell, DC Quantock, THMT van Lierop)
 16. Role of the medical adviser (BW Cromie)
 17. Role of the pharmacist in the clinical evaluation of drugs (AP Launchbury)
 18. Some problems in the clinical evaluation of drugs (HM Lal)
 19. Non-drug adverse reactions (AB Vaidya)
 20. Detecting drug-induced diseases (L Meyler)
- Section IV: Drug evaluation and the law
21. Medicolegal aspects of the evaluation of new drugs (Sir Charles Stuart-Harris)
 22. Some ethical and other aspects of the use of volunteers in pharmaceutical research (DAJ Tyrrell)
 23. Preclinical requirements (MA Neaverson)
 24. Harmonization of drug legislation in the European Economic Community (AY Dubourg)
- Section V: Responses to drugs
25. Variation in drug response due to disease (LF Prescott)
 26. Biological equivalence of therapeutic agents (KC Mezey)
 27. Clinical importance of interindividual differences in pharmacokinetics in man (F Sjöqvist)
 28. Drug interactions with oral anticoagulants (A Breckenridge)
 29. Why not antibiotic combinations? (JC Gould)
 30. Investigating the effects of drug combinations (A Herxheimer)
 31. Drug interactions (CT Dollery)
- Section VI: Use of drugs
32. Clinical evaluation and use of drugs in hospital (GP McNicol)
 33. Clinical evaluation and use of drugs in general practice (D Wheatley)
 34. International variation in drug usage (AJ Jouhar)
 35. Drugs for the future (W Modell)
 36. Role of the medical adviser in promotion (EHL Harries)
 37. Creativity in promotion (S Seltzer)
 38. Ethics of pharmaceutical sales promotion (G Teeling-Smith)
- Section VII: Free communications
39. Clinical pharmacology of monoamine venomotor receptors (F Sicuteri, M Fanciullacci, PL del Bianco, G Franchi)
 40. Lysomones in cellular pathology and therapy (FJ Jacques)
 41. General preclinical considerations for new drug investigation in man (FJ Sanen)
 42. Ventilatory estimates of the efficacy of bronchodilator aerosols (BM Cohen)
- Index

Authors

The Editors are AJ Jouhar (Vice-Chairman, Association of Medical Advisers in the Pharmaceutical Industry and International Medical Director, AB Kabi, Stockholm, Sweden) and MF Grayson (Honorary Secretary of the Association of Medical Advisers in the Pharmaceutical Industry and Department of Rheumatology and Rehabilitation, Royal Free Hospital, London, England). The Foreword is by EC Scowen (Chairman of the UK Committee on Safety of

Medicines and Professor of Medicine, St Bartholomew's Hospital, London, England). The authors are B Berde (Head, Biological and Medical Research Division, Sandoz Ltd, Basle, Switzerland); PL del Bianco (University of Florence, Italy); A Breckenridge (Lecturer, Department of Clinical Pharmacology, Royal Postgraduate Medical School, London, England); BB Brodie (National Heart and Lung Institute, National Institutes of Health, Bethesda, USA); WR Buckett (Pharmacology Section, ICI Ltd, Pharmaceuticals Division, Macclesfield, Cheshire, England); BM Cohen (Associate Professor of Clinical Medicine, The New Jersey College of Medicine and Dentistry, Elizabeth, New Jersey, USA); BW Cromie (Medical Director, Hoechst Pharmaceuticals Ltd, Hounslow, Middlesex, England); CT Dollery (Professor of Clinical Pharmacology, Royal Postgraduate Medical School, London, England); AY Dubourg (Medical Adviser Europe, Abbott Laboratories, Paris, France); M Fanciullacci (University of Florence, Italy); PJ Fell (Department of Clinical Pharmacology, NV Organon, Oss, Holland); JD Fitzgerald (Head of Pharmacology, ICI Ltd, Pharmaceuticals Division, Macclesfield, Cheshire, England); G Franchi (University of Florence, Italy); JC Gould (Director, Central Microbiological Laboratories, Western General Hospital, Edinburgh, Scotland); EHL Harries (Medical Director, Eaton Laboratories, London, England); DE Hathway (Visiting Professor of Chemical Pathology, University of Essex, Colchester, England); A Herxheimer (Senior Lecturer, Department of Pharmacology and Therapeutics, The London Hospital Medical College, London, England); R Hill (Director, Department of Pharmacology, Syntex Research, Palo Alto, California, USA); FJ Jacques (Professor, Laboratory of Clinical Physiology, Louvain, Belgium); HM Lal (Medical Adviser, Searle (India), Bombay, India); AF Lant (Senior Lecturer in Therapeutics, Westminster Hospital Medical School, London, England); AP Launchbury (Pharmaceutical Adviser, Pharmitalia, Barnet, Hertfordshire, England); DR Laurence (Professor of Pharmacology and Therapeutics, University College and University College Hospital Medical School, London, England); THMT van Lierop (NV Organon, Oss, Holland); RE Lister (Head, Biological Sciences Division, Inveresk Research International, Musselburgh, Scotland); C Maxwell (Medical Director, Merrell Division of Richardson=Merrell Ltd, London, England); GP McNicol (Professor of Medicine, University of Leeds, The General Infirmary, Leeds, England); L Meyle (Professor in Clinical Pharmacology, State University, Groningen, Holland); KC Mezey (Vice-Presidents, Medical Sciences, Merck Sharp and Dohme International, New Jersey, USA); JR Mitchell (Head, Clinical Pharmacology-Toxicology, Laboratory of Chemical Pharmacology, National Heart and Lung Institute, Bethesda, Maryland, USA); W Modell (Professor of Pharmacology, Cornell University Medical College, New York, USA); AD Munro-Faure (Director of Clinical Research, The Wellcome Research Laboratories, Beckenham, Kent, England); MA Neaverson (Medical Director, Abbott Australia Pty Ltd, Cronulla, Australia); FB Nicolis (Director of Clinical Research, Lepetit Group, Milan, Italy); LF Prescott (Senior Lecturer in Clinical Pharmacology, University Department of Therapeutics, Edinburgh, Scotland); DC Quantock (NV Organon, Oss, Holland); FJ Sanen (Director of Medical Affairs, Miles Research Division, West Haven, Connecticut, USA); S Seltzer (Managing Director, Intercon International Marketing Ltd, London, England); F Sicuteri (Professor, Faculty of Medicine, Division of Clinical Pharmacology, University of Florence, Italy); F Sjöqvist (Professor of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden); Sir Charles Stuart-Harris (Professor of Medicine, Royal Hospital, Sheffield, England); FM Sullivan (Senior Lecturer, Department of Pharmacology, Guy's Hospital Medical School, London, England); GIM Swyer (Consultant Endocrinologist, Department of Obstetrics and Gynaecology, University College Hospital, London); G Teeling-Smith (Director, Office of Health Economics,

London, England); DAJ Tyrrell (Head of Division of Communicable Diseases, Clinical Research Centre, Harrow, Middlesex, England); AB Vaidya (Clinical Pharmacologist, Ciba Research Centre, Bombay, India); and D Wheatley (Head, General Practitioner Research Group, Twickenham, Middlesex, England).